Gestational trophoblastic neoplasia (GTN) affects reproductive-age women and is highly chemosensitive, with excellent survival outcomes. However, concerns remain regarding the impact of chemotherapy—particularly multiagent regimens—on reproductive and menstrual health.

We aimed to evaluate the effectiveness and safety of single-course initial regimens in patients with low-risk gestational trophoblastic neoplasia (GTN). In this trial (NCT01823315), 276 patients were analyzed.

Although SAE itself may control the growth of the tumour, all patients underwent chemotherapy after successful SAE, and no recurrent massive bleeding occurred during the period of chemotherapy.

Gestational trophoblastic disease treatment depends on the specific type and risk category, and may include surgery, chemotherapy, and radiation. Learn more about the diagnosis and treatments for newly diagnosed and recurrent disease in this expert-reviewed summary.

Therapy-related myeloid neoplasms (t-MNs), including therapy-related myelodysplastic syndrome and therapy-related acute myeloid leukemia, are rare but severe late complications of cytotoxic chemotherapy.

Investigation and treatment of patients with persistent gestational trophoblastic disease and gestational trophoblastic tumours/neoplasia in the United Kingdom.

Abstract Gestational trophoblastic neoplasia (GTN) is extremely rare, but has a very good prognosis, with a cure rate close to 100%, for low-risk diseases. This article describes the case of a healthy 28-year-old nulliparous patient with GTN resistant to multiple lines of treatment.

Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies [2021]

Introduction Gestational trophoblastic neoplasia (GTN) is highly chemosensitive, but resistance to initial chemotherapy remains clinically important despite International Federation of Gynecology and Obstetrics (FIGO) score‐guided management. Evidence on pretreatment predictors of chemoresistance and comparative chemoresistance across chemotherapy regimens remains limited. This study aimed ...

An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275.